How to interpret the broadened development focus for CS014 – an explanation for investors
February 04, 2026
Cereno Scientific has announced that it is broadening the development focus for the drug candidate CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD). The announcement clarifies the direction of CS014’s continued development, focusing on a patient population with very high unmet medical need where both lung disease and pulmonary vascular disease play central roles.
The decision represents an important step in the continued development of CS014 and is intended to create better conditions for the next stage of clinical development. At the same time, Cereno believes that the strategic focus on PH-ILD provides better opportunities for a more efficient and focused development path for CS014, with the potential to shorten the path to market, reduce development complexity, and strengthen the overall likelihood of success. The long-term development strategy for CS014 remains unchanged.
Below, we explain what the decision means, why it has been made, and how it fits into Cereno’s broader development strategy.
What does the announcement mean?
Cereno is broadening the development focus for CS014 from idiopathic pulmonary fibrosis (IPF) to PH-ILD. This means that in the continued clinical development, CS014 will initially be evaluated in a patient population where both fibrotic lung disease and pulmonary vascular involvement are central aspects of the disease.
This is an expansion of the development focus, not a change in direction or a departure from the previous strategy.
What is PH-ILD – and how is it connected to IPF?
Interstitial lung diseases (ILDs) are a group of fibrotic lung diseases. Idiopathic pulmonary fibrosis (IPF) is the most common and well-known form within this group.
In many patients with ILD, including a significant proportion of IPF patients, pulmonary hypertension develops over time – a condition in which pressure in the pulmonary blood vessels increases. When this occurs, the condition is referred to as PH-ILD.
Compared with ILD alone, PH-ILD is associated with:
- Faster disease progression
- Impaired physical capacity
- Significantly poorer prognosis
At the same time, current treatment options remain very limited and are primarily focused on symptom management, meaning there is still a substantial unmet medical need.
Why is the development focus for CS014 being broadened?
CS014 was initially developed with IPF as the primary focus, based on the underlying biology of the disease. At the same time, several key disease-driving processes are shared between IPF and PH-ILD, including fibrosis, thrombosis, inflammation, and pathological vascular remodeling.
By broadening the development focus to PH-ILD, Cereno can:
- Evaluate CS014 in a patient population with more advanced disease and significant unmet medical need
- Better reflect how the disease develops in real-world clinical settings
- Design a Phase II study that takes the complexity of the disease into account
- Strengthen the long-term clinical and strategic potential of CS014
At the same time, PH-ILD represents a more clinically defined and well-characterized patient population, enabling a more focused study design with clearer clinical objectives. Such a design may also allow treatment effects to be identified earlier in development, giving Cereno the opportunity to make important development decisions earlier and based on a stronger clinical foundation.
The lower complexity of the study design also creates conditions for a more targeted use of development resources.
This is not a step away from IPF. On the contrary, IPF remains highly relevant, as many patients with PH-ILD have underlying IPF, and an evaluation of CS014 in IPF without elevated pulmonary pressure may be pursued at a later stage.
What does this mean for continued development?
CS014 has completed a Phase I study in healthy volunteers with a favorable safety and tolerability profile, supporting continued clinical development.
With the broadened development focus, Cereno is now continuing preparations for the next clinical stage. A Phase II study in patients with PH-ILD is planned to be initiated during the first quarter of 2027, with the ambition of conducting a clinical study capable of generating clear and early insights into the potential of CS014.
Overall, this creates conditions for a development process that is both more time-efficient and more resource-focused, while maintaining the scientific ambition of the program.
How does CS014 fit into Cereno’s broader strategy?
CS014 is an important part of Cereno Scientific’s HDAC-based portfolio, together with the company’s lead program CS1 in pulmonary arterial hypertension (PAH).
What the programs have in common is a focus on disease-modifying therapies in serious and rare cardiovascular and pulmonary diseases where current treatment options remain insufficient.
By broadening the development focus for CS014 to PH-ILD, Cereno strengthens the conditions for long-term clinical relevance and a more structured, focused, and efficient continued development of the program, with clearer decision-making support in upcoming clinical stages and patient benefit at the center.